| Product Name | Ganirelix |
| Synonyms | Orgalutran, Antagon, Fyremadel, RS-26306 |
| CAS Number | 123246-29-7 (free base); acetate salt 129311-55-3 |
| Sequence (3-Letter) | Ac-D-Nal(2)-D-Phe(4-Cl)-D-Pal(3)-Ser-Tyr-D-hArg(Et2)-Leu-hArg(Et2)-Pro-D-Ala-NH₂ |
| Sequence (1-Letter) | Ac-[D-2Nal]-[D-4ClPhe]-[D-3Pal]-S-Y-[D-hArg(Et2)]-L-[hArg(Et2)]-P-[D-Ala]-NH₂ |
| Molecular Formula | C₈₀H₁₁₃ClN₁₈O₁₃ (free base) |
| Molecular Weight | 1570.3 (free base) |
| Category | Drug Peptide – GnRH Antagonist |
| Purity | ≥98% (by HPLC) |
| Appearance | White to off-white powder |
| Counter Ion | Acetate (salt form per specification) |
| Peptide Content | ≥80% (per specification) |
| Solubility | Soluble in water and DMSO (highly water-soluble) |
| Storage | -20°C, desiccated, protected from light |
| Available Scale | mg – kg (research quantities to scale-up batches) |
| QC Documentation | COA, HPLC, MS identity (additional API/regulatory documentation on request) |
| Usage | For research and pharmaceutical development use, and as a reference standard or active pharmaceutical ingredient for manufacturing. Not for human or veterinary use; not for sale to patients. Any therapeutic use is subject to applicable regulatory approval. |
Ganirelix is a synthetic decapeptide and a gonadotropin-releasing hormone (GnRH) antagonist, known as a medicine under brand names such as Orgalutran and Antagon (CAS 123246-29-7; acetate salt 129311-55-3). It is a third-generation GnRH antagonist, an analog of natural GnRH with several non-natural and D-amino acid substitutions, including two diethyl-homoarginine residues, an acetyl group at the N-terminus, and a C-terminal amide. We supply it as a white powder for research and pharmaceutical development.
Ganirelix is a GnRH antagonist. It binds the GnRH receptor in the pituitary directly and blocks it, so the pituitary quickly releases less LH and FSH. Because it is an antagonist rather than an agonist, it suppresses these hormones immediately, without an initial surge, and the effect reverses quickly once it is stopped.
Clinically, ganirelix is used in assisted reproduction, where it prevents an early surge of LH during controlled ovarian stimulation so that the eggs stay available for retrieval. This is background information only; the material we supply is for research and pharmaceutical manufacturing use, and is not for human or veterinary use and not for sale to patients.
We supply Ganirelix with a certificate of analysis, HPLC purity data, and mass-spec identity confirmation. Additional documentation for API and regulatory work is available on request, and salt form and purity can be set to your specification.
Yes. We manufacture Ganirelix in-house and supply from research quantities up to scale-up batches. With its several non-natural amino acids it is a demanding synthesis, and we can discuss the right approach for your scale. Contact us with your required purity and quantity for a quote.
Ganirelix is a synthetic decapeptide and a gonadotropin-releasing hormone (GnRH) antagonist, used in assisted reproduction. It is a third-generation GnRH antagonist and is known as a medicine under brand names such as Orgalutran and Antagon. We supply it as a raw material for research and pharmaceutical development.
Ganirelix is a ten-residue peptide based on natural GnRH but substituted at several positions with non-natural and D-amino acids, including two N,N-diethyl-homoarginine residues, an acetyl group at the N-terminus, and a C-terminal amide. These changes give it strong antagonist activity, high water solubility, and good stability. Its free-base CAS number is 123246-29-7 (acetate salt 129311-55-3), its molecular formula is C80H113ClN18O13, and its molecular weight is about 1570.
Ganirelix is a GnRH receptor antagonist. It binds the GnRH receptor in the pituitary directly and blocks it, so the pituitary quickly produces less luteinising hormone (LH) and follicle-stimulating hormone (FSH). Like the other GnRH antagonist cetrorelix, it suppresses these hormones immediately rather than after an initial surge, and because of its short action the pituitary recovers quickly once dosing stops.
Ganirelix is used clinically in assisted reproduction, where it prevents a premature surge of LH during controlled ovarian stimulation, helping keep the developing eggs available for retrieval. This information is provided as scientific and reference background only. The material supplied by SynPeptide is intended for research and pharmaceutical manufacturing, is not for human or veterinary use, and is not for sale to patients; any therapeutic use is subject to applicable regulatory approval.
Because ganirelix contains several non-natural residues, including its diethyl-homoarginine building blocks, it calls for careful synthesis and purification. We supply it with a certificate of analysis, HPLC purity data, and mass-spectrometry identity confirmation, with further documentation available to support active pharmaceutical ingredient and regulatory work, and purity and salt form set to your specification.
We manufacture Ganirelix by solid-phase synthesis, including its non-natural and D-amino acid residues, and supply it from research quantities through to scale-up batches. For related capabilities, see drug peptides, custom peptide synthesis, and peptide modification. Material is supplied for research and pharmaceutical manufacturing use only.
